RxDoctor Payments Data

Gerard Stroup, PA

Physician Assistant · Middletown, DENPI 1730195058

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $6,131 of the $7,059 with a category attached, or 86.9%. 28 manufacturers reported payments, led by Johnson & Johnson at 33.7% of the total. Among physician assistant clinicians in DE with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$7,059in general payments, 2019–2025

Across 411 payments — averaging $17.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$2K
  • AbbVie$1K
  • Novartis$602
  • Regeneron Healthcare Solutions, Inc.$337
  • Sanofi$312
  • UCB, Inc.$294
  • plus $2K from 22 others

What the payments were for

  • Food & beverage$6,13187%
  • Education$92713%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,059 in reported general payments places this provider in the 95th percentile of 527 physician assistant providers in Delaware.

See all physician assistant providers in Delaware

Medicare billing

Part B allowed, 2024
$434,457
Medicare patients
2,123
Services billed
7,263

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent PenDupilumab101$403,581
OtezlaApremilast33$179,052
Enbrel SureclickEtanercept12$84,606
Clobetasol Propionate271$16,599
Ketoconazole683$15,545
Fluorouracil103$7,282
Metronidazole128$6,649
Pimecrolimus15$4,807
Triamcinolone Acetonide254$2,820
Clindamycin Phosphate75$2,636
Mupirocin331$2,475
Mometasone Furoate35$1,187
Doxycycline Hyclate67$1,099
Hydrocortisone140$1,039
ValacyclovirValacyclovir Hcl43$825

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$158$179,05233 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 527 physician assistant providers in Delaware.

Other physician assistant in Middletown

See the full list for Delaware

Where these figures come from

Is this you, or does something look wrong? →